To include your compound in the COVID-19 Resource Center, submit it here.

For sale or rent

How Vicarius plans to deploy series A to help U.S. biotechs launch drugs in EU

Vicarius Pharma AG is fielding a team of experienced regulatory and commercial executives to give U.S. biotechs an option to retain more of the value of their products in Europe.

On Aug. 14, Vicarius said it raised CHF21 million ($21.8 million) in a

Read the full 423 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers